Page 1

SARTORIUS Press Release Aubagne , July 21 , 2021 Half - year results of Sartorius Stedim Biotech ■ Sales revenue up 61.1 percent to 1,352 million euros ; underlying EBITDA margin 36.1 percent Dynamic organic growth ; added momentum from pandemic - related business and acquisitions Forecast for 2021 raised yet again at the beginning of July Sartorius Stedim Biotech , a leading partner of the biopharma industry , has continued on its fast growth trajectory , closing the first half of 2021 with significant double - digit increases in both sales revenue and order intake¹ . " In the first six months of the year , we have seen unabated high demand for innovative technologies used in the production of biopharmaceuticals . Orders from customers who manufacture coronavirus vaccines have played an additional important , though not dominant , role in this respect . The acquisitions closed in 2020 also are performing well and have added positive momentum . Our most recent acquisition of a majority stake in Cell Genix , a leading global supplier of GMP - grade cell culture components , enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug development so that innovative therapies reach patients faster , " said Joachim Kreuzburg , Chairman of the Board of Directors and CEO . " Due to the ongoing expansion of our production facilities worldwide , we are well prepared to respond to the continued high demand , and recruitment of additional employees is continuing at full speed . As communicated at the beginning of July , we significantly raised our sales and earnings forecast for the full year yet again though forecasts are currently subject to above - average uncertainty due to the various pandemic - related effects , " emphasized Kreuzburg . Based on constant currencies , Group sales revenue rose 61.1 percent to 1,352 million euros ( reported : +55.6 percent ) . The majority of this growth was generated through strong organic expansion in all regions . In addition , the ramp - up in coronavirus vaccine production by many manufacturers added around 26 percentage points to the increase in sales revenue . Non - organic growth contributed by the acquisitions² closed in the prior year contributed around 6 percentage points . Order intake grew even more dynamically , rising to 1,890 million euros ( +87.4 percent in constant currencies , of which around 31 percentage points were attributable to the coronavirus pandemic and around 9 percentage points to acquisitions ; reported : +80.2 percent ) . Part of this higher order intake was due to adapted ordering patterns of some customers who in the current situation have been placing their orders further in advance than usual . In the first half , underlying EBITDA¹ was up sharply by 85.8 percent to 487 million euros , while the corresponding margin rose to 36.1 percent ( H1 2020 : 30.2 percent ) . The increase was driven especially by 15